[Market Movement Analysis] Aethlon Medical surged on September 17: North merger + $180 millions financing

1. On September 17, Aethlon Medical signed an all-stock merger agreement with private biotechnology company North Immunology; after the deal closes, the merged company plans to rename itself North Immunology and trade on the Nasdaq Capital Market under the ticker “NRTX.”
2. On September 17, a concurrent oversubscribed private placement is expected to raise approximately $180 million in total, with participants including several healthcare sector institutions; the funds are expected to support operations of the merged company until the second half of 2028.
3. On September 17, North Immunology’s core project, NOR-101, is a half-life extended bispecific antibody targeting IL-13 and IL-18, intended for immune-mediated diseases such as atopic dermatitis; its phase 1a study is expected to initiate in the first quarter of 2027, with interim pharmacokinetic and safety data anticipated mid-2027.

(Disclaimer: This content is a summary generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)